COVID vaccine: Pfizer predicts '94% effectiveness in over-65s'

The coronavirus vaccine developed by Pfizer and BioNTech appears to protect 94% of adults over 65 years old, BBC News reports, citing the companies.

More data released from their ongoing phase three trial suggests it works equally well in people of all ages, races and ethnicities.

The companies say they will now apply for authorisation for emergency use of the jab in the US.

The findings are based on two doses given to more than 41,000 people around the world.

Last week, Pfizer and BioNTech published preliminary data showing the vaccine offered 90% protection against Covid-19 and there were no safety concerns.

This was followed by impressive data on another vaccine, made by US company Moderna, suggesting nearly 95% protection.'

Wednesday's data from Pfizer and BioNTech suggests the vaccine is 95% effective, based on 170 cases of Covid-19 developing in volunteers - just eight were in the group given the vaccine, suggesting it offers good protection.